1．2018年医科院基科费青年医学人才奖励项目，“靶向骨架蛋白FtsZ的新型抗结核天然药物理性化筛选与活性研究”，项目时间2018.10-2019.10，课题经费50万元。

2．2018年度北京市科技新星计划，“抗结核新药发现”，项目时间2018.01-2020.12，课题经费35万元。

3．2017年度国家自然科学基金面上项目，“以FtsZ/SepF蛋白相互作用为靶标的新型特异抗结核活性化合物的发现与分子机制研究”，项目时间2018.01-2021.12，课题经费60.5万元。

4．2014年度国家重大专项“重大新药创制”，耐药结核病药物自主创新及评价关键技术研究平台，主要负责分课题“新型抗结核药物靶标确认”，项目时间2015.01-2018.12，课题经费89.65万元。

5．2013年度国家自然科学基金青年科学基金项目，“结核杆菌FtsZ抑制剂的筛选及其分子机制研究”，项目时间2014.01-2016.12，课题经费23万元。

6．2012年度药物研究所基本科研业务费专项项目，科研重点与团队建设专项，“抗耐药感染药理的新分子机制研究”，项目时间2013.01-2014.12，课题经费24万。

发表论文：

1.   Song W, Zhang H, Zhang Y, Chen Y, Lin Y^#, Han Y^#, Jiang J^#. Identification and characterization of Zika virus NS5 methyltransferaseinhibitors. Front Cell Infect Microbial. 2021;11: 665379.

2.   Song W, Zhang H, Zhang Y, Li R, Han Y, Lin Y^#, Jiang J^#. Repurposing clinical drugs is a promising strategy to discover drugsagainst zika virus infection. Front. Med. 2021; 15 (3): 404-415.

3.   Lin Y, Zhang H, Song W, Si S, Han Y, Jiang J. Identification andcharacterization of Zika virus NS5 RNA-dependent RNA polymerase inhibitors. IntJ Antimicrob Agents. 2019; 54(4): 502-506.

4.    Lin Y,Zhang H, Zhu N, Wang X, Han Y, Chen M, Jiang J, Si S.Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosisactivity. Tuberculosis (Edinb). 2018;110: 79-85.

5.    Lin Y, Li Y, Zhu N, Han Y, Jiang W, Wang Y, Si S,Jiang J. The antituberculosis antibioticcapreomycin inhibits protein synthesis bydisrupting interaction between ribosomal proteins L12 and L10. Antimicrob Agents Chemother. 2014; 58(4):2038-2044.

6.    Lin Y, Zhu N, Han Y, Jiang J, Si S.Identification of anti-tuberculosis agents thattarget the cell-division protein FtsZ. JAntibiot (Tokyo), 2014; 67(9): 671-676.

7.    Lin Y,Li Y, Zhu Y, Zhang J, Li Y, Liu X, Jiang W, Yu S, You XF, Xiao C, HongB, Wang Y, Jiang JD, Si S. Identificationof antituberculosis agents that target ribosomal protein interactions using ayeast two-hybrid system. Proc Natl Acad Sci USA. 2012; 109(43): 17412-17417.

8.    Lin Y, Chen S, Si S, Xie Y. Expression,purification, crystallization and preliminary X-ray crystallographic analysisof the hyperthermophilic nucleotidyltransferase TTHA1015 from Thermusthermophilus HB8. Acta Cryst. 2011;F67, 235-237.

9.    Zhu N*, Lin Y*, Li D, Gao N, Liu C,You X, Jiang J, Jiang W, Si S. Identification of ananti-TB compound targeting the tyrosyl-tRNA synthetase. J Antimicrob Chemother. 2015; 70(8): 2287-2294.

10.    Zhu Y*,Lin Y*, Liu X, Hu W,Wang Y. Identification of AcAP5 as anovel factor Xa inhibitor with both direct and allosteric inhibition. Biochem Biophys Res Commun. 2017;483(1): 495-501.

11.     Zhu Y, LinY, Liu A, Shui M, Li R, Liu X, Hu W, Wang Y. Structure-guided creation ofAcAP5-derived and platelet targeted factor Xa inhibitors. Biochem Pharmacol. 2015; 95(4): 253-262.

12.  Zhu N, Wang X, Li D, Lin Y, You X, Jiang J, Xu Y, Jiang W,Si S. IMB-T130 targets 3-dehydroquinate synthase and inhibits Mycobacteriumtuberculosis. Sci Rep. 2018; 8:17439.

13.  Li D, Gao N, Zhu N, Lin Y, Li Y, Chen M, You X, Lu Y, Wan K, Jiang JD, Jiang W, Si S. Discoveryof the disubstituted oxazole analogues as a novel class anti-tuberculoticagents against MDR- and XDR-MTB. Bioorg Med Chem Lett. 2015; 25(22): 5178-5181.

14.  Zhu Y, Li R, Lin Y, Shui M, Liu X, Chen H, Wang Y. Engineering Factor Xainhibitor with multiple platelet-binding sites facilitates its platelettargeting. Sci Rep. 2016; 6: 29895.

15.  Feng R, Shou JW, Zhao ZX, He CY, Ma C, HuangM, Fu J, Tan XS, Li XY, Wen BY, Chen X, Yang XY, Ren G, Lin Y, Chen Y, You XF, Wang Y, Jiang JD. Transforming berberine into its intestine-absorbable form bythe gut microbiota. Sci Rep. 2015; 5:12155.

16.  Wang Y, Shou JW, Li XY, Zhao ZX, Fu J, HeCY, Feng R, Ma C, Wen BY, Guo F, Yang XY, Han YX, Wang LL, Tong Q, You XF, Lin Y, Kong WJ, Si SY, Jiang JD.Berberine-induced bioactive metabolites of the gut microbiota improve energymetabolism. Metabolism. 2017; 70:72-84.

17.  Li N, Wang X, XuY, Lin Y, Zhu N, Liu P, Lu D, Si S. Identification of a novel liver X receptor agonist thatregulates the expression of key cholesterol homeostasis genes with distinctpharmacological characteristics. MolPharmacol. 2017; 91(4): 264-276.

18.  Wang Y, Tong Q, Shou JW, Zhao ZX, Li XY, ZhangXF, Ma SR, He CY, Lin Y, Wen BY, GuoF, Fu J, Jiang JD. Gut microbiota-mediatedpersonalized treatment of hyperlipidemia using berberine. Theranostics. 2017; 24(9): 2443-2451.

19.  林媛，张红娟，韩燕星，蒋建东。小檗碱对肠道菌的抑制作用。中国医药生物技术，2018，13(4)：335-338.

20.  林媛，司书毅，蒋建东。小檗碱的抗菌作用。药学学报，2018，53(2)：163-168.

21.  林媛，朱宁屿，蒋建东，司书毅。以FtsZ为靶点的抗结核药物筛选模型的建立及应用。中国抗生素杂志，2015，40(3)，166-170.

22.  林媛，朱宁屿，蒋建东，司书毅。靶向FtsZ先导化合物的筛选及其抗结核作用探讨。中国新药杂志，2015，24(5)，592-594.

专利：

1.    结核菌核糖体蛋白L12和L10相互作用阻断剂筛选模型及应用。ZL 2011 1 0079787.1

2.    Screening model for blockers of interaction between ribosomalproteins L12 and L10 of tubercle bacillus and use thereof. (PCT/CN2012/073020).